Clinical Trials at University of Virginia Health System
As of August 2026, 49 paid clinical trials are recruiting at University of Virginia Health System, located at 1215 LEE ST, CHARLOTTESVILLE, VA 22908-0001, phone (434) 924-0000 in Charlottesville, Virginia. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Heart Failure and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
49 clinical trials at University of Virginia Health System
·Clear filters·A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
The Ailliance Post-Market Clinical Study
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
A Study of BI 3810944 in Patients With Advanced Cancer
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Common conditions studied in Charlottesville
- Acute Myeloid Leukemia (11 active studies)
- Heart Failure (8 active studies)
- Breast Cancer (7 active studies)
- Endometrial Cancer (7 active studies)
- Prostate Cancer (7 active studies)
- Atrial Fibrillation (6 active studies)
Leading research sponsors in Charlottesville
- University of Virginia
- National Cancer Institute (NCI)
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Charlottesville?
There are approximately 530 recruiting clinical trials in Charlottesville, Virginia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Charlottesville pay participants?
Most recruiting trials in Charlottesville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Charlottesville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Charlottesville?
The most common conditions under active study in Charlottesville include Acute Myeloid Leukemia (11), Heart Failure (8), Breast Cancer (7), Endometrial Cancer (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Charlottesville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Charlottesville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Charlottesville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Charlottesville?
Recruiting research sites in Charlottesville include University of Virginia, University of Virginia Cancer Center, University of Virginia Health System, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Charlottesville right now?
The largest active categories in Charlottesville are Cancer & tumors (187), Cardiovascular (38), Neurology & pain (36). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Virginia Health System?
University of Virginia Health System is located at 1215 LEE ST, CHARLOTTESVILLE, VA 22908-0001. Use the Google Maps link in the intro above to get directions.
How do I contact University of Virginia Health System?
You can reach University of Virginia Health System by phone at (434) 924-0000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.